Canakinumab

A Contract Award Notice
by NORTHERN HEALTH AND SOCIAL CARE TRUST

Source: Find a Tender
Type: Contract ()
Duration: not specified
Value: £120K

Sector: MISCELLANEOUS
Published: 26 Jun 2025
Delivery: not specified
Deadline: n/a

Concepts

Location

Geochart for 1 buyers and 1 suppliers

1 buyer

Northern Health & Social Care Trust Antrim

1 supplier

Novartis Pharmaceuticals London

Description

The intended contract is for the supply of Canakinumab to Northern Health and Social Care Trust for up to a maximum of 3 years

Award Detail

1	Novartis Pharmaceuticals (London) Canakinumab Reference: 1 Value: £120,000

CPV Codes

None found

Legal Justification

Purchase of drugs which are subject to patent protection/ Sole MA Holder, where no reasonable alternative or substitute exists. Section 41 schedule 5(5) of the PA2023 permits a direct award in the case of single supplier and permits the award if the following conditions are met in relations to the public contract - (a)due to a particular supplier having intellectual property rights or other exclusive rights, only that supplier can supply the goods, services or works required, and (b)there are no reasonable alternatives to those goods, services or works.